EQS-News: Formycon AG / Key word(s): Agreement/AllianceFormycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab) 02.02.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release February 2, 202.
Investegate announcements from Formycon AG, Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Formycon AG / Key word(s): Agreement/AllianceFormycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)01-Feb-2023 / 17:40 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS Ne.
EQS-Ad-hoc: Formycon AG / Key word: Agreement/Alliance
Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1
01-Feb-2023 / 17:40. | February 1, 2023